<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306370</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017804-95</org_study_id>
    <secondary_id>TRA-81</secondary_id>
    <nct_id>NCT01306370</nct_id>
  </id_info>
  <brief_title>Fibrin Glue or Tranexamic Acid for Total Knee Arthroplasty</brief_title>
  <acronym>ATRHEMOS</acronym>
  <official_title>Prevention of Postoperative Blood Loss: Randomised Unicentric Parallel Clinical Trial That Assess the Efficacy of Fibrin Glue and Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      a) Principal: To assess if the fibrin glue or the tranexamic acid reduce less than 20% the&#xD;
      blood losses with respect to the habitual haemostasia in patients with arthroplasty total of&#xD;
      knee.&#xD;
&#xD;
      Secondaries: To assess the treatment safety. To perform a cost- analyses.&#xD;
&#xD;
      Methods: Randomized, unicentric, and parallel clinical trial with four comparative groups:&#xD;
      Tissucol® (fibrin glue), fibrin glue manufactured by the Cryoseal® system (Banc de Sang i&#xD;
      Teixits de Catalunya), tranexamic acid and habitual haemostasia.&#xD;
&#xD;
      Nº of participant centres: 1. Random allocation will be centralised.&#xD;
&#xD;
      Main outcome: Blood losses (ml) in the post-operatory period collected by the habitual drain&#xD;
      system.&#xD;
&#xD;
      Secondary outcomes: Proportion of patients with blood transfusion, complications of surgery&#xD;
      wound, pre and post-operative haemoglobin, units of blood transfused, post-operative&#xD;
      mortality, days of hospital stay, safety of interventions assessed.&#xD;
&#xD;
      Size sample calculation: The number needed of patients is 172 (43 per group) to demonstrate a&#xD;
      20% difference in the post-operative blood losses between the treatments assessed and the&#xD;
      habitual haemostasia, with a statistical power of 80% and a 0.05 bilateral alpha, and a 20%&#xD;
      of withdrawals.&#xD;
&#xD;
      Statistical analysis: The investigators will perform a comparison of outcomes through the &quot;t&quot;&#xD;
      test, the Mann-Whitney test of chi square, depending of the evaluated outcomes, quantitative&#xD;
      or ordinals or qualitative, respectively. The software used will be Statistical Package for&#xD;
      the Social Sciences (SPSS) version 17.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative blood loss (mL)</measure>
    <time_frame>During the first 48h after the surgical intervention</time_frame>
    <description>Blood loss (mL) by the surgical wound collected by drain systems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that need a postoperative blood transfusion</measure>
    <time_frame>During the first postoperative week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with surgical wound infection</measure>
    <time_frame>During the first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with surgical wound dehiscence</measure>
    <time_frame>During the first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with re-intervention by wound complications</measure>
    <time_frame>During the first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deep venous thrombosis</measure>
    <time_frame>During the first postoperative week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain of surgical wound</measure>
    <time_frame>During the first postoperative week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Units of blood transfusion</measure>
    <time_frame>During the first postoperative week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length stay</measure>
    <time_frame>Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>During the first postoperative month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Knee Arthropathy</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrin glue BSTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is homologous fibrin glue from a single blood donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tissucol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is fibrin glue commercialized from multiple donors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual haemostasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.&#xD;
Each dosage: 2 ampoules of 500mg/5 mL/ampoule</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Amchafibrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin glue</intervention_name>
    <description>Topical administration, before to close the surgical wound. Dosage: 2 mL.</description>
    <arm_group_label>Tissucol</arm_group_label>
    <other_name>Tissucol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibrin glue</intervention_name>
    <description>Topical administration, before to close the surgical wound.</description>
    <arm_group_label>Fibrin glue BSTC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Habitual haemostasis</intervention_name>
    <description>The surgical habitual haemostasis.</description>
    <arm_group_label>Habitual haemostasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Total knee arthroplasty&#xD;
&#xD;
          -  The patient consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance drugs to the study or to bovine protein (aprotinin)&#xD;
&#xD;
          -  Antecedent of thromboembolic disease&#xD;
&#xD;
          -  Patient with cardiac alterations of the rhythm&#xD;
&#xD;
          -  Patients with valvular cardiac prosthesis&#xD;
&#xD;
          -  Patients with pro-thrombotic alterations of coagulation&#xD;
&#xD;
          -  Treatment with anticonceptive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martinez Zapata, Mª José</last_name>
    <role>Study Director</role>
    <affiliation>Centro Cochrane Iberoamericano. Servicio de Epidemiología Clínica y Salud Pública. IIB Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aguilera Roig, Xavier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu i Sant Pau. IIB Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary knee arthroplasty</keyword>
  <keyword>fibrin glue</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>topic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

